Aprea Therapeutics, Inc.
NASDAQ: APRE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Oren Gilad
- Employees
- 8
- Headquarters
- Boston, United States
- IPO year
- 2019
- Market cap
- $5.2M
- Website
- https://atrinpharma.com
Loading APRE…
Loading profile data…Frequently asked questions about APRE
What does Aprea Therapeutics, Inc. (APRE) do?
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a cli...
Where does APRE trade?
Aprea Therapeutics, Inc. (APRE) trades on the NASDAQ Global Select.
What sector is APRE in?
Aprea Therapeutics, Inc. (APRE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Aprea Therapeutics, Inc.?
Oren Gilad is the chief executive officer of Aprea Therapeutics, Inc. (APRE).
Where is Aprea Therapeutics, Inc. headquartered?
Aprea Therapeutics, Inc. is headquartered in United States.
Does APRE pay a dividend?
Aprea Therapeutics, Inc. (APRE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did APRE go public?
Aprea Therapeutics, Inc. (APRE) completed its initial public offering in 2019.